News und Analysen
2 Magnificent Dividend Stocks to Buy and Hold Forever
Dividends are one of investors' most powerful tools for earning strong returns over the long run. Buying shares of strong dividend-paying companies and reinvesting the payout allows compounding to
Is It Time to Dump Your Shares of Pfizer?
A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and
Why AbbVie Stock Flopped on Friday
AbbVie's (NYSE: ABBV) products are regularly used to help heal the sick, but the company's stock wasn't healthy for portfolios on Friday. The company published its latest quarterly earnings release
Fenimore Sells Off All 244K WAT Shares Valued At $85.1 Million
Fenimore Asset Management Inc. fully exited its position in Waters Corporation (NYSE:WAT), selling approximately $85.09 million in shares.
According to a Q3 2025 filing submitted to the U.S
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.
This list
3 Dividend-Paying Drug Stocks to Buy at a Discount
The S&P 500 index was recently offering a tiny dividend yield of 1.2%. You can get as much as 7% from some of the world's largest drugmakers. But sometimes, a high yield is a sign of risk.
What does
Should You Buy Pfizer Stock Before Nov. 4?
One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and question marks
Intuitive Surgical vs. Medtronic: Which Stock Is the Better Buy?
Intuitive Surgical (NASDAQ: ISRG) has dominated the market for robotic-assisted surgery (RAS) devices for the better part of the last 20 years, with little competition to speak of in many of the
2 Unstoppable Health Care Giants to Buy Right Now for Less Than $1,000
Being a big company comes with a lot of positives. But there are negatives, too. Some businesses end up imploding under their own weight because they face increased scrutiny and competition and
Prediction: Vertex Pharmaceuticals Will Be Worth More Than Pfizer by 2030
Vertex Pharmaceuticals (NASDAQ: VRTX) and Pfizer (NYSE: PFE) are both among the largest drugmakers in the world. The latter currently has the edge in this department, with a market cap of $141
3 Healthcare Stocks Paying the Highest Dividends of 2025
A big dividend yield is nice to see, but it shouldn't be the only thing you look at when buying a stock. The actual business behind the yield is, in fact, more important. That's why you'll need to
Growth Fund Dumps $25 Million in Vertex Stock as Weak Quarter Hit Returns
On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third
Is UnitedHealth Still a Good Dividend Stock?
UnitedHealth Group (NYSE: UNH) has been a top dividend stock to own for years. It has consistently provided investors with a reliable dividend, and it has made generous increases to the payout over
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
Dividend investors shouldn't be dissuaded from investing just because the S&P 500 (SNPINDEX: ^GSPC) has a miserly 1.2% yield. If you dig in a bit, you can find attractive dividend stocks, including
2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever
It isn't all that difficult to find high-yield dividend stocks -- say, those paying out at more than 4%. The real trick is finding a company that produces sufficient profitability and free cash flow
1 Top Dividend Growth Stock to Buy Right Now
Dividend stocks are arguably worth a premium in the current environment. Between a prolonged government shutdown and President Donald Trump's trade wars, the economy and the market might be heading
AbbVie Draws Growing Institutional Confidence As Investors Seek Steady Growth
Image source: Getty Images
LOS ANGELES CAPITAL MANAGEMENT LLC increased its position in AbbVie by 304,281 shares during Q3 2025, an estimated $61.96 million trade based on the average price for Q3
Investment Firm Verity & Verity Loads Up With 908,000 Pfizer (PFE) Shares Worth $22.4 Million
Verity & Verity, LLC disclosed in its Oct. 21, 2025, SEC filing a purchase of 907,855 shares of Pfizer Inc. valued at an estimated $22.41 million for the quarter ended Sep. 30, 2025.
According to a
Prediction: Here's Where UnitedHealth Stock Is Headed After Scaling Back Medicare Advantage Plans
Some might view UnitedHealth Group (NYSE: UNH) as a stock and a company in retreat. UnitedHealth's shares have plunged more than 40% below the high set in the fourth quarter of 2024. The health
AbbVie: Navigating Challenges and Seizing Opportunities in the Pharma Sector
Explore the exciting world of AbbVie (NYSE: ABBV) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (NASDAQ:BIIB) during the third quarter for an estimated $16.1 million.
In a quarterly disclosure filed with the
2 High-Yield Dividend Stocks Too Cheap to Ignore
What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock. One that is trading at attractive levels is even more preferable. Excellent dividend payers
Whale Watching: Iconic Healthcare Stock Gains Additional Institutional Support, According to Recent Filing
Burns Matteson Capital Management, LLC reported a new stake in UnitedHealth Group (NYSE:UNH), acquiring 8,017 shares in the third quarter of 2025, an estimated $2.77 million trade as of the end of
ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million
On October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV disclosed in an SEC filing that it sold out of Pfizer(NYSE:PFE), with an estimated $2.66 million trade.
According to a Securities and
QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market
On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (NYSE:PFE), adding shares worth an estimated $6.8 million in the third quarter.
QSM Asset Management increased its position in


